Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance

After the diagnosis of prostate cancer, many men alter their lifestyle or diet or use various supplements in an attempt to retard the growth of their cancer. While there is limited data on the use of diet and supplements to alter the risk of prostate cancer, even less is known regarding the ability of diet or supplements to alter progression. For men who have elected active surveillance, the investigators propose to investigate the ability of vitamin D to retard the growth of prostate cancer.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Vitamin D (Calcitriol)

Phase: N/A

Eligibility

Ages Eligible For Study:

45 Years - N/A

Inclusion Criteria

- Untreated prostate adenocarcinoma by an extended biopsy (>8 needle cores on systematic prostate biopsy) within 1 year of the screening date - PSA <10.0 ng/ml - Gleason sum 6 or <2 mm Gleason pattern 4 - No more than 33% of biopsy cores positive

External Links

Explore related trials

Contact information

Primary Contact:

Cancer Clinical Trials Office CCTO 6504987061

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: